# Advances in Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/amyloid-beta-aggregation-alzheimers-disease-advances/ > **Published:** 2026-03-26T14:08:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:28-04:00 > **Clinical Summary:** Explore amyloid beta aggregation Alzheimer's disease research and advances in neuroinflammation targeting for improved cognitive health outcomes. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Alzheimer’SNeuroinflammationCurcuminNatural ProductsCognitive Health Journal Cells Study Type Clinical Study Population Human participants Why This Matters [Alzheimer’s disease](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/) affects over 6 million Americans with limited therapeutic options, making research into neuroprotective compounds clinically relevant. This review examines natural products like curcumin and resveratrol that patients frequently ask about for cognitive health. Clinical Summary This appears to be a narrative review examining natural compounds targeting amyloid beta aggregation and neuroinflammation in [Alzheimer’s disease](https://cedclinic.com/cannabis-alzheimer-treatment-research-2025/) pathophysiology. The study focuses on curcumin, resveratrol, and other natural products as potential therapeutic interventions. However, without access to the full methodology and results, the clinical significance remains unclear. Most natural product research in Alzheimer’s has shown limited translation from preclinical promise to clinical efficacy. Dr. Caplan’s Take “I see patients regularly asking about these compounds for cognitive protection, but the evidence gap between laboratory studies and meaningful clinical outcomes remains substantial. Until we have rigorous clinical trial data, I counsel patients about realistic expectations while acknowledging the general safety profile of these compounds.” Clinical Perspective 🧠 Clinicians should interpret natural product research cautiously, distinguishing between mechanistic plausibility and clinical efficacy. Patients interested in these approaches should understand that promising laboratory findings don’t guarantee therapeutic benefit, and any cognitive concerns warrant comprehensive medical evaluation rather than relying on supplements alone. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Targeting%20Amyloid%20Beta%20Aggregation%20and%20Neuroinflammation%20in%20Alzheimer%27s%20Disease%3A...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41677657/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41677657/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Targeting%20Amyloid%20Beta%20Aggregation%20and%20Neuroinflammation%20in%20Alzheimer%27s%20Disease%3A...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41677657/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41677657/](https://pubmed.ncbi.nlm.nih.gov/41677657/) Table of Contents - [FAQ](#FAQ)[What role does amyloid beta aggregation play in Alzheimer’s disease progression?](#What_role_does_amyloid_beta_aggregation_play_in_Alzheimer8217s_disease_progression) - [How does neuroinflammation contribute to Alzheimer’s disease?](#How_does_neuroinflammation_contribute_to_Alzheimer8217s_disease) - [What are the current limitations of conventional Alzheimer’s treatments?](#What_are_the_current_limitations_of_conventional_Alzheimer8217s_treatments) - [Can natural products like curcumin help with Alzheimer’s disease?](#Can_natural_products_like_curcumin_help_with_Alzheimer8217s_disease) - [Should patients consider natural supplements for cognitive health based on this research?](#Should_patients_consider_natural_supplements_for_cognitive_health_based_on_this_research) - [Related](#Related) ## FAQ #### What role does amyloid beta aggregation play in Alzheimer’s disease progression? Amyloid beta (Aβ) aggregation is recognized as a central mechanism driving Alzheimer’s disease pathology. The accumulation of these protein aggregates in the brain contributes to neuronal dysfunction and is closely linked with neuroinflammatory processes that accelerate [cognitive decline](https://cedclinic.com/cannabis-cognitive-safety-in-older-adults/). #### How does neuroinflammation contribute to Alzheimer’s disease? Neuroinflammation is an interlinked mechanism with amyloid beta aggregation that drives Alzheimer’s disease progression. This [inflammatory response](https://cedclinic.com/synthetic-cannabinoid-win55212-2-mesylate-rheumatoid-arthritis/) in the brain tissue exacerbates neuronal damage and [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), making it a key therapeutic target alongside amyloid pathology. #### What are the current limitations of conventional Alzheimer’s treatments? Current pharmacological approaches have significant limitations in modifying the underlying disease pathology of Alzheimer’s. These treatments primarily address symptoms rather than targeting the root causes like amyloid aggregation and neuroinflammation, highlighting the need for alternative therapeutic strategies. #### Can natural products like curcumin help with Alzheimer’s disease? Natural products such as curcumin and resveratrol show promise in targeting both amyloid beta aggregation and neuroinflammation in Alzheimer’s disease. However, this represents early-stage evidence requiring further clinical validation before these approaches can be recommended for therapeutic use. #### Should patients consider natural supplements for cognitive health based on this research? While natural products show potential benefits, this research represents monitored relevance requiring additional evidence before clinical action. Patients should consult with healthcare providers before making supplement decisions, as more robust [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) are needed to establish safety and efficacy profiles. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Targeting Amyloid Beta Aggregation and Neuroinflammation in Alzheimer’s Disease: Advances and Future Directions.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41677657/”, “about”: “cells clinical study targeting amyloid beta”, “isPartOf”: “Cells”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence CBD Gummies and Alzheimer's: What the Evidence Shows for Cognitive and Behavioral Support An overview of current evidence on CBD gummies for cognitive and behavioral support in Alzheimer's patients. Read More [Unregulated Substance Abuse and Systemic Inflammation Markers: A Review.](https://cedclinic.com/inflammatory-biomarkers-unregulated-substance-use-review/) Reviewing the impact of substance abuse on systemic inflammation, relevant to neuroinflammatory processes. [Explore Insights](https://cedclinic.com/inflammatory-biomarkers-unregulated-substance-use-review/) [Lifestyle and Behavioral Enhancements of Sleep: A Review.](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) Examining lifestyle factors that improve sleep quality, important for cognitive health in neurodegenerative diseases. [Learn More](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).